Novogen, Genentech deal

Roche's Genentech unit granted Novogen exclusive, worldwide rights to develop and commercialize GDC-0084, a phosphoinositide 3-kinase (PI3K) inhibitor. Novogen expects to begin a Phase II trial to tre...